Everyone knows the antibiotic R&D story: it's a graveyard. Low returns, short courses, stewardship that (correctly) restricts use the moment a drug launches, and a decade of companies going bankrupt after approval. So here is a genuinely surprising finding. In a radar where oncology accounts for more than 40% of everything, the second-most-pursued protein across all our accelerating compounds is a bacterial enzyme — beta-lactamase, the mechanism bacteria use to chop up penicillins and cephalosporins and shrug off front-line antibiotics. Only TNF-alpha ranks higher. The chemistry that neutralizes antibiotic resistance is quietly one of the strongest things we're seeing. That deserves an explanation.
From the Knitify Pharma Demand Radar — our running read on where pharmaceutical demand is heading. We publish the observations; the method behind them stays in-house.
A whole class, moving together
What makes this a signal rather than a fluke is that it isn't one molecule. It's the entire modern toolkit of resistance-breaking inhibitors — the newer class built to restore antibiotic activity against the resistant enzymes that broke the previous generation of drugs — accelerating together, alongside the antibiotics they're designed to protect. Some are already approved; others are still in development. When a whole class advances at once, you're not looking at a single company's program. You're looking at a field-wide response to a moving target.
The reason is the resistance itself. As multidrug-resistant Gram-negative infections spread, each newly dominant enzyme creates demand for the next inhibitor that can neutralize it. [1] That's a treadmill — and treadmills generate steady, compounding demand, which is exactly what we're picking up.
The science, and why it never finishes
Bacteria don't make one enzyme; they make families of them. The serine beta-lactamases — the KPC, CTX-M and OXA types — are what today's approved inhibitors were built to neutralize. But the harder problem is the metallo-beta-lactamases (NDM, VIM, IMP), which use a zinc-based chemistry the current inhibitors largely don't touch. That gap is precisely where the accelerating chemistry is aimed, and it's why the class keeps advancing rather than settling: every inhibitor that closes one door opens the search for the next.
The distinction is chemical, and it is the whole story. A serine beta-lactamase carries a reactive serine residue that springs the beta-lactam ring open and inactivates the antibiotic; the diazabicyclooctane inhibitors that define the current generation slip into that same active site and tie up the serine in a reversible covalent embrace, sparing the partner antibiotic. A metallo-beta-lactamase works on a completely different principle — it uses one or two zinc ions to activate a water molecule that hydrolyzes the ring. There is no serine to trap, so an inhibitor engineered for serine chemistry has nothing to grab. That single fact is why the newest, most celebrated inhibitors leave the metallo-enzymes almost untouched, and why the frontier has moved to zinc-chelating and dual-mechanism designs meant to cover both.
The urgency isn't commercial hype. The World Health Organization's 2024 Bacterial Priority Pathogens List puts carbapenem-resistant Enterobacterales and Acinetobacter in its highest, "critical" tier — carbapenem-resistant Klebsiella pneumoniae topped the ranking. [2] Those are exactly the bugs beta-lactamase inhibitors exist to rescue antibiotics against. Most of them still carry serine carbapenemases such as KPC, which the newest inhibitors can neutralize — but a growing and dangerous share are acquiring the metallo-enzymes the current toolkit can't reach, and that rising share is where the demand is headed next.
The treadmill nobody steps off
Resistance is not an accident; it is evolution doing what evolution does. Every course of an antibiotic applies selection pressure — the bacteria carrying a resistance gene survive and multiply while the susceptible ones die off — and many beta-lactamases ride on plasmids, mobile loops of DNA that bacteria trade with one another across species lines. A gene that surfaces in one organism can be circulating in an unrelated pathogen a short time later, which is why resistance to a new agent so often appears before the agent has even finished its commercial launch.
That is the engine under the word "treadmill": a new inhibitor restores a family of antibiotics, the restored pressure selects for a variant enzyme that evades it, and the field answers with the next inhibitor. From a supplier's vantage point the operative word is not "crisis" but "recurring." A one-and-done cure would be a wonderful outcome and a terrible business; a permanent arms race is a durable, compounding source of demand for the chemistry that keeps the fight winnable.
The broken economics of a good antibiotic
Here is the paradox at the center of the whole category. In almost every other therapeutic area, a better drug sells more; in antibiotics, a better drug should sell less. The moment a genuinely novel agent clears approval, stewardship programs — correctly — lock it away as a reserve, to be used only when older drugs have failed, so resistance to it emerges as slowly as possible. The reward for inventing something valuable is that everyone agrees to use as little of it as they can. Volume — the thing that normally repays a decade of development — is suppressed by design.
The results have been brutal and repetitive. More than once over the past decade, a company has won approval for a real, needed, scientifically impressive antibiotic and then failed commercially anyway — unable to write enough prescriptions to cover its costs, and forced into bankruptcy or a fire-sale of the very asset regulators had just blessed. Capital drew the obvious conclusion: investors and large pharmaceutical companies retreated, leaving a shrinking band of specialists to carry an entire pillar of modern medicine. This is the graveyard the opening referred to, and it is not exaggerated.
How pull incentives reshape the demand
Governments have started to fix that broken math with "pull" incentives that pay for access rather than units. The UK's health system now runs a subscription — often called the "Netflix model" — paying a fixed annual fee for a new antibiotic regardless of how much is used, and the United States has debated the same idea in the PASTEUR Act. This matters for demand because it decouples the chemistry's value from prescription volume: the reward is to have the drug ready, stockpiled, and manufacturable — which turns steady, policy-driven demand for the underlying ingredient into something a supplier can actually plan around.
The shift is subtle but consequential. A push incentive funds the research; a pull incentive rewards the finished, available product — and it changes what the buyer is buying. Under a subscription, a health system is paying for readiness: for the drug to exist, be quality-assured, and be manufacturable at scale on short notice, whether or not this year's case count justifies it. That converts a jagged, unpredictable prescription stream into something closer to a standing order — and a standing order is something a supplier can staff, tool and finance against. For the ingredient beneath the finished product, that is the difference between a market you avoid and one you can build toward.
Who this actually touches
The demand doesn't land on a single kind of company. Specialty active-ingredient suppliers — the firms that make the complex molecules at the heart of these inhibitors and their partner antibiotics — sit closest to the signal; their live question is which chemistries to build capacity for before the orders show up. Contract development and manufacturing organizations are asked to hold the surge-ready capacity a pull model implicitly pays for. And generics makers matter more than the newness of the field suggests: many of the workhorse beta-lactams these inhibitors are paired with are long off-patent, so the combination products lean on a reliable, affordable supply of both halves.
Governments and public-health bodies have become the new anchor buyers — writing the subscriptions, funding the stockpiles, and, through priority lists, effectively naming the targets the whole supply chain should prepare for. Together these stakeholders trace a clean line from science to commerce: a shift in enzyme biology tells you which chemistry will be needed, a shift in policy tells you who will pay for it, and the intersection tells a supplier where a durable position might be worth building.
The surprise, the opportunity — and the caveats
None of this is a free lunch. Antibiotics face some of the steepest regulatory hurdles in medicine, and solving the chemistry is not the same as clearing the clinic. An inhibitor, moreover, is rarely sold on its own — it reaches patients as one half of a fixed combination product, which ties its commercial fate to the antibiotic it's paired with and the approval of the pair together. And the demand we're describing is, to an unusual degree, policy-dependent: subscription models and stockpiling programs are political commitments that can expand, stall or reverse with a change of government or budget. Anyone reading this signal is, implicitly, also taking a view on whether the policy holds.
With those caveats stated plainly, the shape of the opportunity is still unusual. The pessimism about antibiotic economics is real — but it has hollowed out the competition. Unlike the oncology clusters, where dozens of well-funded players crowd every target, this space is thin, specialized, and driven as much by public-health necessity and government pull-incentives as by ordinary market demand. Durable, compounding demand plus few competitors is the exact profile of an underpriced lane.
The point here isn't that antibiotics are a good business in the abstract. It's that the demand — at the molecule level — is real and accelerating, and thinly contested. That's where a defensible sourcing decision starts, and the specific molecules and buyers are the part we keep for subscribers.
Editorial commentary from the Knitify Pharma Demand Radar. Not investment, legal, regulatory, or medical advice.